Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG CSLCT-AML-11-73

Title
A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse
Principal Investigator
Jessica Altman
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG CSLCT-AML-11-73
Purpose
The main purpose of the study is to find out the safety and effectiveness of repeat doses of CSL362 at increasing dose levels.
Overview
Acute myeloid leukemia(AML) is often not cured because of rare cells called “leukemic stem cells” that are not killed by chemotherapy. It may take only few of these cells need to survive for the leukemia to grow back. It is believed that these leukemic stem cells' destruction is key cure AML. Lab studies show that CSL362 targets these rare cells, stops their growth,and kills them.CSL362 is an investigational (drug not approved by the U.S. Food & Drug Administration[FDA]). This study will determine how safe and well tolerated CSL362 is in participants who are at risk for an early relapse (cancer returns)of AML.
Eligibility
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older.
  • Participants must have completed treatment for AML and achieved complete remission (the disappearance of all signs of cancer).
  • Participants must have a life expectancy of 5 months or greater.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants will receive CSL362 intravenously (through a vein) once every 2 weeks for a period of 10 weeks. Participants will receive 6 doses unless their study doctor finds it in their best interest to stop.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Jessica Altman

last updated: 22-Sep-14 09:17 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.